FDA.reportPublic FDA data

atoltivimab-maftivimab-odesivimab-ebgn 483.3 MG / 483.3 MG / 483.3 MG in 14.5 ML Injection

RxCUI
2571682
RxNorm name
atoltivimab-maftivimab-odesivimab-ebgn 483.3 MG / 483.3 MG / 483.3 MG in 14.5 ML Injection
Display name
atoltivimab-maftivimab-odesivimab-ebgn 483.3 MG / 483.3 MG / 483.3 MG in 14.5 ML Injection
Full name
atoltivimab-maftivimab-odesivimab-ebgn 483.3 MG / 483.3 MG / 483.3 MG in 14.5 ML Injection
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:38:46

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761169Inmazebatoltivimab, maftivimab, and odesivimab-ebgn351(a)Rx2026-08-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
InmazebATOLTIVIMAB, MAFTIVIMAB, AND ODESIVIMAB-EBGNRegeneron Pharmaceuticals, Inc.0536b6fe-6fe5-4fd6-8cc6-1b481945c1fa2025-12-15Warnings, Adverse reactionsExact identifier
rxcui: 2571682

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
0536b6fe-6fe5-4fd6-8cc6-1b481945c1faatoltivimab-maftivimab-odesivimab-ebgn 483.3 MG / 483.3 MG / 483.3 MG in 14.5 ML Injection [PSN] · 14.5 ML atoltivimab-ebgn 33.3 MG/ML / maftivimab-ebgn 33.3 MG/ML / odesivimab-ebgn 33.3 MG/ML Injection [SCD] · atoltivimab-ebgn 33.33 MG/ML / maftivimab-ebgn 33.33 MG/ML / odesivimab-ebgn 33.33 MG/ML per 14.5 ML Injection [SY] · atoltivimab-ebgn 483.3 MG / maftivimab-ebgn 483.3 MG / odesivimab-ebgn 483.3 MG per 14.5 ML Injection [SY] · atoltivimab-maftivimab-odesivimab-ebgn 483.3 MG / 483.3 MG / 483.3 MG per 14.5 ML Injection [SY]512These highlights do not include all the information needed to use INMAZEB safely and effectively. See full prescribing information for INMAZEB. INMAZEB ® (atoltivimab, maftivimab, and odesivimab-ebgn) injection, for intravenous use Initial U.S. Approval: 202020251215